ArticleBMJ open2013
Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study.
Article in BMJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Adherence to Oral Antineoplastic Therapies.The oncologist · 2016Pooled it
- Trial
- Article
- Domains of Structured Oral Anticancer Medication Programs: A Scoping Review.Oncology nursing forum · 2022Article
- ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications.Oncology nursing forum · 2022Article
- Investigation of Intervention Solutions to Enhance Adherence to Oral Anticancer Medicines in Adults: Overview of Reviews.JMIR cancer · 2022Review
- Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study.Breast cancer research and treatment · 2022Article
- Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.Cancer chemotherapy and pharmacology · 2020Observational
- Patient-Oncologist Communication Regarding Oral Chemotherapy During Routine Office Visits.JCO oncology practice · 2020Article
- Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review.Journal of the National Cancer Institute · 2020Article
- Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Article
- A Novel Approach to Better Characterize Medication Adherence in Oral Anticancer Treatments.Frontiers in pharmacology · 2018Article
- Patient-doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center.Patient preference and adherence · 2018Article
- Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice.Frontiers in pharmacology · 2016Article
- Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.Cancer letters · 2015Article
- Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.BMC research notes · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and evaluate a multiprofessional modular medication management to assure adherence to capecitabine.
methodsThe study was conducted as a prospective, multicentred observational cohort study. All participants received pharmaceutical care consisting of oral and written information. Daily adherence was defined as percentage of days with correctly administered capecitabine doses and assessed using medication event monitoring. According to their daily adherence during the first cycle, patients were identified as initially non-adherent (<90% adherence) or adherent (≥90% adherence). Initially non-adherent patients received additional adherence support.
resultsSeventy-three patients with various tumour entities were enrolled, 58 were initially adherent and 15 non-adherent. Median daily adherence of initially non-adherent patients increased from 85.7% to 97.6% during the observation period of six cycles. Throughout all cycles, median daily adherence of initially adherent patients was 100.0%. Daily adherence was not associated with sociodemographic and disease-related factors. No patient was non-persistent.
conclusionsAn early adherence screening effectively distinguishes between patients adhering and non-adhering to capecitabine. The provision of specific adherence support is associated with enhanced adherence of initially non-adherent patients, whereas initially adherent patients remain adherent for at least six cycles without specific support. Our needs-based approach helps to use available resources for adherence management efficiently.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.